Short Interest in Intensity Therapeutics Inc. (NASDAQ:INTS) Decreases By 40.2%

Intensity Therapeutics Inc. (NASDAQ:INTS) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 48,911 shares, a drop of 40.2% from the August 15th total of 81,764 shares. Based on an average daily trading volume, of 45,186 shares, the short-interest ratio is presently 1.1 days. Approximately 1.6% of the company’s stock are short sold.

Intensity Therapeutics Price Performance

NASDAQ:INTS remained flat at $3.81 during mid-day trading on Wednesday. 8,247 shares of the company traded hands, compared to its average volume of 41,632. The stock has a market cap of $12.42 million, a P/E ratio of -1.07 and a beta of 2.76. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. Intensity Therapeutics has a 1-year low of $3.51 and a 1-year high of $43.50. The company has a 50 day moving average price of $4.36 and a two-hundred day moving average price of $4.93.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). On average, equities analysts forecast that Intensity Therapeutics will post -2.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

INTS has been the topic of a number of research analyst reports. HC Wainwright upped their target price on Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Finally, Benchmark reiterated a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.